fda bpc 157 warning letter unapproved new drug Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling US signals crackdown on compounded

US signals crackdown on compounded weight loss drugs; Hims shares tumble Reuters fda warning letter bpc 157 unapproved new drug The U.S. Food and Drug Administration is moving FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and FDA is moving to restrict mass marketed compounded GLP 1 products that aren't FDA approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Sends Warning Letters to More Than 50 GLP 1 Compounders and Manufacturers Wilson Sonsini

SKU: 74015383436 · From uqtrucking.com